profit from every $100 of sales.
$0$100
United Therapeutics
$591.17-0.36% today
+27.9% in 1 year
1-year low $462.301-year high $608.49
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $18.86 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What United Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $1.94 billion in 2022 to $3.18 billion in 2025, with $1.33 billion of profit last year.
SalesProfit
United Therapeutics handed back 98% of the cash it generated last year.
Buybacks $1.0B
Free cash flow 2025$1.0B
Bought back its own shares$1.0B
Paid as dividends–
United Therapeutics vs. similar companies
United Therapeutics grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| United Therapeutics | 18.9× · Fair price | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads United Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,483 | 1,686 | 1,936 | 2,328 | 2,877 | 3,183 | |
| 1,375 | 1,563 | 1,785 | 2,070 | 2,568 | 2,798 | |
| 594 | 556 | 980 | 1,185 | 1,448 | 1,517 | |
| 712 | 662 | 1,034 | 1,387 | 1,654 | 1,819 | |
| 515 | 476 | 727 | 985 | 1,195 | 1,335 | |
| 11.54 | 10.06 | 15.00 | 19.81 | 24.64 | 27.86 | |
| 92.7% | 92.7% | 92.2% | 88.9% | 89.2% | 87.9% | |
| 40.0% | 33.0% | 50.6% | 50.9% | 50.3% | 47.7% | |
| 34.7% | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 4,615 | 5,169 | 6,045 | 7,167 | 7,364 | 7,880 |
| Cash | 739 | 895 | 961 | 1,208 | 1,697 | 1,557 |
| Total debt | – | – | 800 | 700 | 300 | – |
| Total liabilities | 1,220 | 1,210 | 1,248 | 1,182 | 920 | 784 |
| 3,395 | 3,959 | 4,797 | 5,985 | 6,444 | 7,096 | |
| 45 | 47 | 49 | 50 | 49 | 48 | |
| 15.4% | 12.2% | 13.9% | 15.8% | 18.5% | 19.3% | |
| 15.2% | 12.0% | 15.2% | 16.5% | 18.5% | 18.8% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 756 | 598 | 803 | 978 | 1,327 | 1,561 | |
| 59 | 121 | 139 | 230 | 247 | 526 | |
| 696 | 477 | 664 | 748 | 1,081 | 1,035 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | 11 | 14 | 1,012 | 1,017 | |
| 164 | 139 | 107 | 39 | 144 | 148 |
Valuation
- 18.9×
- 20.1×
- 0.98
- 4.2×
- 7.9×
- 24.3×
- 13.0×
- 4.1%
- 5.3%
- 0.0%
Profitability
- 87.9%
- 47.7%
- 41.9%
- 54.2%
- 18.8%
- 14.9%
- 19.2%
- 19.2%
- 23.5%
- 17.0%
Growth
- +16.5%
- +19.3%
- −3.7%
- –
- −0.3%
Financial health
- -0.6×
- 0.00
- 0.0%
- 87.6×
- 4.79
- 4.50
- 0.47
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 10%of 963
Top 3%of 894
Top 31%of 632
Top 33%of 908
Top 28%of 991
What analysts expect
- Average price target
- $610.67
- Range
- $519.00 – $700.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 5.82 | 7.00 | −16.9% |
| Feb 25, 2026 | 7.70 | 7.13 | +8.0% |
| Oct 29, 2025 | 7.16 | 6.89 | +3.9% |
| Jul 30, 2025 | 6.41 | 7.29 | −12.1% |
| Apr 30, 2025 | 6.63 | 6.29 | +5.4% |
| Feb 26, 2025 | 6.19 | 6.40 | −3.3% |
| Oct 30, 2024 | 6.39 | 6.43 | −0.6% |
| Jul 31, 2024 | 5.85 | 6.40 | −8.6% |
News
Manchester United sacks its manager as it looks to turn around a woeful seasonSeeking Alpha · Nov 12, 2026United Microelectronics October revenue rises 18.3% Y/YSeeking Alpha · Nov 5, 2026United Fire Group outlines ~10% growth pace as it sees ~0.5-point expense ratio improvement potentialSeeking Alpha · Nov 4, 2026Mark Cuban Warns Hyperscaler Borrowing Could Create A “Debt Bubble In The United States Of America”Yahoo Finance · Oct 29, 2026United Rentals subsidiary prices $2.5B debt dealSeeking Alpha · Oct 27, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
85Pass
Benjamin Graham
72Pass
Philip Fisher
93Pass
Peter Lynch
85Pass
Joel Greenblatt
54No pass
Charlie Munger
84Pass
Terry Smith
77Pass
Questions about United Therapeutics
Is United Therapeutics a good stock to buy?
A strong, very profitable business at a fair price. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the United Therapeutics AI analysis
What does United Therapeutics do?
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It is in Biotechnology, based in Silver Spring, MD, United States, with 1,400 employees.
Does United Therapeutics pay a dividend?
No. United Therapeutics does not pay a dividend at the moment; in 2025 it returned $1.02 billion to shareholders by buying back its own shares.
Is United Therapeutics stock halal?
No. United Therapeutics does not pass our halal screen: interest is about 6% of its revenue. How we check
How has United Therapeutics stock done over the past year?
Up 27.9% over the past twelve months, to $591.17. It traded between $462.30 and $608.49 and is 2.8% below its high.
Who are United Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with United Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.